Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for Oncology Fellows. He also produces print content for OncologyLive, as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com
Lutetium-PSMA Appears Safe in Locally Advanced High-Risk Prostate Cancer
September 11th 2021Treatment with neoadjuvant lutetium prostate-specific membrane antigen followed by radical prostatectomy exhibited a favorable safety profile in patients with locally advanced high-risk prostate cancer.
Read More
Kaiku Health and Novartis Collaborate on Specialized Digital Patient Monitoring Technology
June 15th 2021Kaiku Health has announced that they are partnering with the global healthcare company Novartis to develop a digital patient monitoring and management system specifically for patients with melanoma who are receiving BRAF/MEK combination therapies.
Read More
Nivolumab Plus Chemotherapy Outperforms Chemotherapy Alone in Resectable NSCLC
June 6th 2021Neoadjuvant nivolumab in combination with platinum-doublet chemotherapy significantly improved pathological complete response rates and had a greater depth of pathological response compared with chemotherapy alone in patients with resectable non–small cell lung cancer.
Read More
Loncastuximab Tesirine Provides Alternative for Broad Range of Patients With DLBCL
June 1st 2021Loncastuximab tesirine-lpyl (Zynlonta) exhibited significant clinical activity, including impressive response rates with tolerable safety, as a single agent in adult patients with relapsed/refractory large B-cell lymphoma that failed prior established therapies.
Read More
TJ-CD4B Aims to Expand the Bispecific Antibody Portfolio as Phase 1 Trial Kicks Off
April 27th 2021I-Mab Biopharma and ABL Bio, Inc set their sights on adding the bispecific antibody, TJ-CD4B, to the expanding armamentarium for patients with various types of advanced and metastatic solid cancers.
Read More